Hexa Reports Market Research Reports and Insightful Company Profiles
Parkinson's Disease Therapeutics in Major Developed Market Size, Share, Growth, Treatment, Analysis, Symptoms, Emerging Trends and Opportunities to 2021
Summary Parkinson's Disease (PD) is a progressive, chronic neurodegenerative condition, which is currently incurable. It is associated with old age, and characterized by the loss of neurons in the substantia nigra region of the brain. The global Parkinson's Disease (PD) prevalence was estimated at 16.1 million in 2011, and after Alzheimer's disease it is the second most common neurodegenerative disease worldwide. Parkinson's Disease (PD) is a progressive disease and, although not fatal, it can develop severe symptoms and complications that significantly impact upon the patient's quality of life. Symptoms for each stage can be categorized into early, moderate and advanced stages. Major motor symptoms of Parkinson's Disease (PD) include tremors and difficulty walking. Parkinson's Disease (PD) also gives rise to non-motor symptoms, such as dementia, depression, hallucinations and loss of taste and smell.
Browse Detail Report With TOC @ http://www.hexareports.com/report/parkinsons-diseasetherapeutics-in-major-developed-markets/details
There are several different drug classes available to relieve Parkinson's Disease (PD) symptoms. The aim is for treatments to increase dopamine levels, which is substantially diminished in brains affected by
Hexa Reports Market Research Reports and Insightful Company Profiles Parkinson's Disease (PD). The most common therapies include levodopa, dopamine agonists and Monoamine Oxidase-B (MAO-B) inhibitors, with the choice of therapies dependent on patient symptoms and lifestyle. As the disease develops, the medication will need to be taken more strictly, due to the effect of drugs wearing off (known as off- time), which causes symptoms to return before the next dose. With the current marketed drugs focusing primarily on symptomatic relief, Parkinson's Disease (PD) remains incurable, with a huge unmet need for disease-modifying therapies. However, due to the lack of clearly established clinical trial methodologies, replication of the benefits demonstrated by neuroprotective agents in the laboratory to human trials has proved challenging. More importantly, due to an incomplete understanding of the underlying mechanisms that cause the disease, a viable therapeutic target to halt or slow disease progression is currently not in scope, which limits the effectiveness of current product development programs. Scope - A brief introduction to Parkinson’s Disease (PD), including pathogenesis, disease staging, diagnosis and treatment algorithms - Comprehensive analysis of the drugs available for the treatment of PD, covering their safety, efficacy, treatment patterns, and strengths/weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy - Comprehensive analysis of the pipeline for Parkinson’s Disease (PD) therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period, on the basis of Phase distribution, molecule type and molecular target - Additional thorough analysis of pipeline drug clinical trials by Phase, molecule type, trial size, trial duration, and program failure rate for each molecule type and mechanism of action - Multi-scenario market forecast data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain Discussion of the drivers of and barriers to market growth - Discussion of the licensing and co-development deals landscape in Parkinson’s Disease (PD), by stage of development, molecule type and mechanism of action, as well as analysis of both licensing and codevelopment deals by year, and network maps of licensing and co-development deals Reasons to buy - Understand the different levels of Parkinson’s Disease (PD) therapy from early-stage to advanced - Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent - Observe the trends in clinical trial duration and size among clinical Phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or forthcoming developmental programs for Parkinson’s Disease (PD) therapeutics
Hexa Reports Market Research Reports and Insightful Company Profiles - Observe the trends in clinical trial duration and size among clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for Parkinson’s Disease (PD) therapeutics - Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the Parkinson’s Disease (PD) therapeutics market Request A Sample copy of This Report @ http://www.hexareports.com/sample/104174
Table of Contents 1 Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 7 2 Introduction 9 2.1 Disease Introduction 9 2.2 Symptoms 9 2.3 Etiology 10 2.3.1 Genetic Factors 10 2.3.2 Environmental Factors 11 2.3.3 Aging 11 2.4 Pathophysiology 12 2.5 Epidemiology 13 2.6 Disease Stages 14 2.7 Co-morbidities and Complications 15 2.8 Diagnosis 15 2.9 Assessment of Disease Severity 16 2.9.1 Hoehn and Yahr scale 16 2.9.2 Unified Parkinson’s Disease Rating Scale 16 2.10 Treatment 17 2.10.1 Pharmacological Therapies 18 2.10.2 Non-pharmacological Treatments 20 2.11 Treatment Algorithm 21 2.11.1 Early Parkinson’s Disease 21 2.11.2 Advanced Parkinson’s Disease 22 3 Marketed Products 25 3.1 Overview 25 3.1.1 Dopamine Replacement Therapies 25 3.1.2 MAO-B Inhibitors 28 3.1.3 Dopamine Agonists 30
Hexa Reports Market Research Reports and Insightful Company Profiles 3.1.4 COMT Inhibitors 35 3.1.5 Other Drugs Targeting Non-motor Symptoms of PD 39 3.2 Comparative Efficacy and Safety 40 4 Pipeline for Parkinson’s Disease 44 4.1 Overview 44 4.2 Pipeline Distribution by Mechanism of Action/Molecular Target 46 4.3 Clinical Trials 49 4.3.1 Failure Rate 49 4.3.2 Clinical Trial Duration 51 4.3.3 Clinical Trial Size 53 4.3.4 Comparison of Average Trial Metrics by Phase and Mechanism of Action 55 4.4 Promising Pipeline Molecules 56 4.4.1 Opicapone – Bial 56 4.4.2 Nuplazid (pimavanserin) – Acadia Pharmaceuticals 58 4.4.3 Nurelin (Amantadine Hydrochloride Extended-Release) – Adamas Pharmaceuticals 59 4.4.4 Tozadenant – Biotie Therapies 60 4.4.5 APL-130277 (apomorphine hydrochloride) – Cynapsus Therapeutics 61 4.4.6 P2B001 (pramipexole dihydrochloride + rasagiline mesylate) – Pharma Two B 63 4.4.7 DM-1992 (levodopa + carbidopa extended release) – Depomed 63 4.4.8 CVT-301 (levodopa) – Acorda Therapeutics 65 4.4.9 Dipraglurant Immediate-Release– Addex Therapeutics 65 4.4.10 Accordion Pill (levodopa and carbidopa) – Intec Pharma 66 4.4.11 ND-0612L (levodopa and carbidopa) – NeuroDerm 67 4.5 Heatmaps of Safety and Efficacy for Parkinson’s Disease Pipeline and Marketed Products 69 4.6 Pipeline Product Heat Map and Product Competitiveness Framework 73 Browse Full Report @ http://www.hexareports.com/report/parkinsons-disease-therapeutics-in-majordeveloped-markets/details
About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Hexa Reports Market Research Reports and Insightful Company Profiles
Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States Phone Number 1-800-489-3075 Email Us: sales@hexareports.com Our Website: http://www.hexareports.com/ Visit Our Blogs: http://hexareports.blogspot.in